BRPI0914223A2 - derivados de tiofeno ou tiazol e seus usos como inibidores de p13k - Google Patents

derivados de tiofeno ou tiazol e seus usos como inibidores de p13k

Info

Publication number
BRPI0914223A2
BRPI0914223A2 BRPI0914223A BRPI0914223A BRPI0914223A2 BR PI0914223 A2 BRPI0914223 A2 BR PI0914223A2 BR PI0914223 A BRPI0914223 A BR PI0914223A BR PI0914223 A BRPI0914223 A BR PI0914223A BR PI0914223 A2 BRPI0914223 A2 BR PI0914223A2
Authority
BR
Brazil
Prior art keywords
thiophene
inhibitors
thiazole derivatives
thiazole
derivatives
Prior art date
Application number
BRPI0914223A
Other languages
English (en)
Inventor
C Renou Christelle
P Cardin David
L Gaulin Jeffrey
D Greenspan Paul
Vyskocil Stepan
Xu Tianlin
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41010579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0914223(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of BRPI0914223A2 publication Critical patent/BRPI0914223A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0914223A 2008-06-19 2009-06-17 derivados de tiofeno ou tiazol e seus usos como inibidores de p13k BRPI0914223A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13248408P 2008-06-19 2008-06-19
PCT/US2009/003607 WO2009154741A1 (en) 2008-06-19 2009-06-17 Thiophene or thiazole derivatives and their use as pi3k inhibitors

Publications (1)

Publication Number Publication Date
BRPI0914223A2 true BRPI0914223A2 (pt) 2019-09-24

Family

ID=41010579

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914223A BRPI0914223A2 (pt) 2008-06-19 2009-06-17 derivados de tiofeno ou tiazol e seus usos como inibidores de p13k

Country Status (21)

Country Link
US (3) US8183240B2 (pt)
EP (1) EP2313399B1 (pt)
JP (1) JP5596026B2 (pt)
KR (1) KR20110018451A (pt)
CN (1) CN102066365A (pt)
AU (1) AU2009260782B2 (pt)
BR (1) BRPI0914223A2 (pt)
CA (1) CA2727069A1 (pt)
CL (1) CL2010001474A1 (pt)
CO (1) CO6331431A2 (pt)
CR (1) CR20110032A (pt)
EA (1) EA201170052A1 (pt)
ES (1) ES2491522T3 (pt)
GE (1) GEP20125650B (pt)
IL (1) IL210055A0 (pt)
MA (1) MA32468B1 (pt)
MX (1) MX2010014125A (pt)
NZ (1) NZ589844A (pt)
UA (1) UA106206C2 (pt)
WO (1) WO2009154741A1 (pt)
ZA (1) ZA201008875B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2250160B1 (en) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
NZ589844A (en) * 2008-06-19 2012-11-30 Millennium Pharm Inc Thiophene or thiazole derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CA2750935A1 (en) * 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
WO2012021611A1 (en) * 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
NZ607087A (en) * 2010-08-11 2015-05-29 Millennium Pharm Inc Heteroaryls as inhibitors of pi3k and for the treatment of proliferative, inflammatory, or cardiovascular disorders
JP2013533318A (ja) * 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリールおよびその使用
JP5726635B2 (ja) 2010-08-25 2015-06-03 株式会社Ｎｔｔドコモ マルチモードフロントエンド回路
AR083450A1 (es) 2010-10-13 2013-02-27 Millennium Pharm Inc Heteroarilos y sus usos en el tratamiento de enfermedades proliferativas, inflamatorias o cardiovasculares
CN102503930B (zh) * 2011-10-28 2014-07-02 浙江大学 3,4,5,-三取代氨基噻吩类化合物及其制备和用途
WO2013088404A1 (en) 2011-12-15 2013-06-20 Novartis Ag Use of inhibitors of the activity or function of PI3K
JP2015506347A (ja) * 2011-12-23 2015-03-02 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヘテロアリールおよびその使用
CN107267554A (zh) 2012-03-14 2017-10-20 萨克生物研究学院 腺病毒肿瘤诊断法
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
MX2015011899A (es) 2013-03-15 2016-05-05 Genentech Inc Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
MX2016010604A (es) * 2014-02-14 2017-04-27 Univ British Columbia Compuestos de dominio de unión a ácido desoxirribonucleico (dbd a adn) del receptor de andrógeno humano como terapéuticos, y métodos para su uso.
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
KR20220163505A (ko) 2016-02-23 2022-12-09 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
WO2020261144A1 (en) 2019-06-28 2020-12-30 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
CN110759900B (zh) * 2019-10-25 2021-07-30 沈阳药科大学 噻吩类化合物的制备方法和用途
AU2020406139A1 (en) 2019-12-20 2022-06-30 Bayer Aktiengesellschaft Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof
CN113527281B (zh) * 2020-04-20 2023-12-22 昆山彭济凯丰生物科技有限公司 杂环化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD275870A1 (de) 1988-09-27 1990-02-07 Univ Leipzig Verfahren zur herstellung von in 5-position verschiedenartig substituierten 3-aminothiophen-4-carbonitrilen
WO2006078287A2 (en) 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
DK2024372T3 (da) 2006-04-26 2010-09-20 Hoffmann La Roche Thieno[3,2-d]pyrimidin-derivat, der er egnet som P13K inhibitor
JP2009535386A (ja) * 2006-05-03 2009-10-01 アストラゼネカ アクチボラグ チアゾール誘導体および抗腫瘍剤としてのその使用
AU2007287428B2 (en) 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
CA2704711C (en) * 2007-09-24 2016-07-05 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
EP2250160B1 (en) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
NZ589844A (en) * 2008-06-19 2012-11-30 Millennium Pharm Inc Thiophene or thiazole derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors

Also Published As

Publication number Publication date
NZ589844A (en) 2012-11-30
US8183240B2 (en) 2012-05-22
CN102066365A (zh) 2011-05-18
CA2727069A1 (en) 2009-12-23
WO2009154741A1 (en) 2009-12-23
AU2009260782B2 (en) 2014-12-11
CO6331431A2 (es) 2011-10-20
JP5596026B2 (ja) 2014-09-24
UA106206C2 (ru) 2014-08-11
US20120202812A1 (en) 2012-08-09
EP2313399A1 (en) 2011-04-27
MA32468B1 (fr) 2011-07-03
JP2011524904A (ja) 2011-09-08
KR20110018451A (ko) 2011-02-23
CR20110032A (es) 2011-03-14
US20130217689A1 (en) 2013-08-22
ZA201008875B (en) 2012-02-29
AU2009260782A1 (en) 2009-12-23
CL2010001474A1 (es) 2011-04-29
MX2010014125A (es) 2011-02-24
US8440664B2 (en) 2013-05-14
US20100075951A1 (en) 2010-03-25
WO2009154741A8 (en) 2010-03-25
IL210055A0 (en) 2011-02-28
ES2491522T3 (es) 2014-09-08
EA201170052A1 (ru) 2011-06-30
EP2313399B1 (en) 2014-05-28
GEP20125650B (en) 2012-09-25

Similar Documents

Publication Publication Date Title
BRPI0914223A2 (pt) derivados de tiofeno ou tiazol e seus usos como inibidores de p13k
BR112012000660A2 (pt) compostos heterociclos e seus usos
BR112012003709A2 (pt) compostos heterocíclicos e usos dos mesmos
BRPI1016150A2 (pt) compostos heterocíclicos e seus usos.
BRPI0908906A2 (pt) compostos heterocíclicos e usos dos mesmos
BRPI0919322A2 (pt) derivados de glicosideo e usos dos mesmos como inibidores sglt
BR112012013175A2 (pt) 2-amino-5,5-diflúor-5,6-di-hidro-4h-oxazinas como inibidores de bace 1 e/ou bace 2
BRPI0906625A2 (pt) Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
BRPI0920767A2 (pt) Tiazóis substituídos por heterociclila como agentes protetores de cultura
BRPI1011066A2 (pt) "pirazolopirimidinas e heterociclos relacionados como inibidores de quinase
BRPI0906980A2 (pt) Composição de derivados e maleatados
BRPI0909185A2 (pt) Derivado de vitamina e e seus usos
BRPI1012679A2 (pt) derivados de piperidina e piperazina como inibidores de autotaxina
BRPI0917557A2 (pt) artigo absorvente com componente de barreira
BRPI0820544A2 (pt) 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
BRPI0911228A2 (pt) compostos e composições como inibidores de proteínas quinase
BRPI0716477A2 (pt) Derivados heteroarila como inibidores de quinase protéica
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BRPI0820722A2 (pt) Derivados de tiazol usados como inibidores de pi 3 cinases
BRPI1012770A2 (pt) derivados de tiofeno
BRPI0812825A2 (pt) Derivados ftalazinona como inibidores de parp-1
BRPI0920183A2 (pt) derivados de fenetilamida e seus analogos heterociclicos
BRPI0811044A2 (pt) 2-morfolin-4-il-pirimidinas como inibidores de p13k.
DOP2011000397A (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
BRPI0921862A2 (pt) inibidores de raf e seus usos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.